SOURCE-LINKED STUDY SUMMARY
Semaglutide modulates explore/exploit decision-making in major depressive disorder: A randomized clinical trial.
Full paper summarizedQuality not appraised
- What was studied
- A secondary trial analysis examined semaglutide effects on modeled decision strategies, not general intelligence.
- Who / model studied
- 72 adults with major depression, overweight/obesity and cognitive difficulties; semaglutide versus placebo.
- Studied dose & schedule
- Oral semaglutide titrated from 3 to 14 mg over eight weeks, versus placebo alongside usual treatment; 16-week study.
- What the study found
- The model suggested more use of known high-reward choices, exploration of uncertain options and choice repetition. However, adjusted task-performance comparisons were not significant, and the parent trial found no executive-function benefit.
- Limitations & context
- Main paper reviewed; supplements not reviewed. Exploratory model changes are not percentages of cognitive improvement. Possible unblinding and underpowered mediation analyses limit claims about direct brain effects independent of weight loss. Detailed safety counts were not supplied by this secondary analysis.
Read summary source ↗ · Prepared 10/28/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1017/s0033291726106412